Increased bone resorption in HD patients: Is it caused by elevated RANKL synthesis?

Nephrology Dialysis Transplantation

Volumn 20, Issue 3, 2005, Pages 566-570

  Avbersek Luznik, Ivica ^a   Balon, Breda Peĉovnik ^b   Rus, Igor ^a   Marc, Janja ^c  

^a General Hospital Jesenice   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Bone biochemical markers; Bone turnover; Osteoprotegerin ligand; Parathyroid hormone; RANKL; Renal osteodystrophy

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; ALUMINUM HYDROXIDE; CALCIUM; CALCIUM CARBONATE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHATE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE REMODELING; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; FEMALE; HEMODIALYSIS PATIENT; HUMAN; IN VITRO STUDY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ACID PHOSPHATASE; ADULT; AGED; ALKALINE PHOSPHATASE; BONE RESORPTION; CARRIER PROTEINS; CASE-CONTROL STUDIES; COLLAGEN; FEMALE; GLYCOPROTEINS; HUMANS; ISOENZYMES; KIDNEY FAILURE, CHRONIC; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OSTEOCALCIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RENAL DIALYSIS;

EID: 15044348241     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh672     Document Type: Article

References (16)

1. Hruska K. New concepts in renal osteodystrophy. Nephrol Dial Transplant 1998; 13: 2755-2760
2. Monier-Faugere MC, Malluche HH. Role of cytokines in renal osteodystrophy. Curr Opin Nephrol Hypertens 1997; 6: 327-632
3. Montalban C, Garcia-Unzueta MT, DeFrancisco ALM, Amado JA. Serum interleukin-6 in renal osteodystrophy: relationship with serum PTH and bone remodeling markers. Horm Metab Res 1999; 31: 14-17
4. Yasuda H, Shima N, Nakagawa N et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1988; 95: 3597-3602
5. Huang JC, Sakata T, Pfelger LL et al. PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 2004; 19: 235-244
6. Hofbauer LC, Heufelder AE. The role of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. Clinical review 114: hot topic. J Clin Endocrinol Metab 2000; 85: 2355-2363
7. Yasuda H, Shima N, Nakagawa N et al. A novel molecular mechanism modulating osteoclast differentiation and function. Bone 1999; 25: 109-113
8. Yasuda H, Shima N, Nakagawa N et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998; 139: 1329-1337
9. Lacey DL, Timos E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176
10. Kazama JJ, Shigematsu T, Yano K et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002; 39: 525-532
11. Coen G, Ballanti C, Balducci A et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 2002; 17: 233-238
12. Avbersek-Luznik I, Malesic I, Rus I, Marc J. Increased levels of osteoprotegerin in hemodialysis patients. Clin Chem Lab Med 2002; 40: 1019-1023
13. Alvarez L, Peris P, Guañabens N et al. Serum osteoprotegerin and its ligand in Paget's disease of bone. Arthritis Rheum 2003; 48: 824-828
14. Terpos E, Szydlo R, Apperley JF et al. Soluble receptor activator of nuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003; 102: 1064-1069
15. Ziolkowska M, Kurowska M, Radzikowska A et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor α treatment. Arthritis Rheum 2002; 46: 1744-1753
16. Rubin MR, Bilezikian JP. The anabolic effects of parathyroid hormone therapy. Clin Geriatr Med 2003; 19: 415-432